Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

5.7K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.7K
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

810
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
810

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Introducing the 2026 Early Career Board of <i>ACS Medicinal Chemistry Letters</i>.

ACS medicinal chemistry letters·2026
Same author

Harnessing FBXO31 with Terminal Amide-Functionalized Molecules for Targeted Protein Degradation.

Journal of the American Chemical Society·2026
Same author

Covalent Reprogramming of Kinase Binders to Modulate Protein Abundance.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Same author

Heterobifunctional proteomimetic polymers for targeted degradation of MYC and KRAS.

Nature communications·2026
Same author

Photochemical cyclization of α-amino esters to access 3-azetidinones.

Chemical science·2026
Same author

Harnessing FBXO31 with terminal amide-functionalized molecules for targeted protein degradation.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: Jul 30, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K

Rational Design of Highly Potent and Selective Covalent MAP2K7 Inhibitors.

Dalton R Kim1, Meghan J Orr1, Ada J Kwong1

  • 1Department of Chemistry, Northwestern University, Evanston, Illinois 60208, United States.

ACS Medicinal Chemistry Letters
|May 17, 2023
PubMed
Summary

Researchers designed novel irreversible inhibitors targeting MAP2K7 (also known as MEK7), a key enzyme in T cell acute lymphoblastic leukemia (T-ALL). These compounds show promise as research tools for pediatric T-ALL.

More Related Videos

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.1K
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

605

Related Experiment Videos

Last Updated: Jul 30, 2025

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.4K
Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules
10:58

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

17.1K
Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay
06:17

Covalent Fragment Screening Using the Quantitative Irreversible Tethering Assay

Published on: February 28, 2025

605

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The mitogen-activated protein kinase (MAPK) cascade regulates crucial cellular processes like proliferation and differentiation.
  • MEK (MAP2K) enzymes are central to MAPK signaling, controlling signal divergence and cross-talk.
  • MAP2K7 (MEK7/MKK7) is implicated in the molecular pathophysiology of pediatric T cell acute lymphoblastic leukemia (T-ALL).

Purpose of the Study:

  • To rationally design, synthesize, and evaluate a novel class of irreversible MAP2K7 inhibitors.
  • To develop potential research tools for investigating pediatric T-ALL.

Main Methods:

  • Rational drug design and synthesis of novel chemical entities.
  • In vitro evaluation of inhibitor potency and selectivity.
  • Assessment of cellular activity in relevant models.

Main Results:

  • A streamlined one-pot synthesis was developed for the novel inhibitors.
  • The compounds demonstrated favorable in vitro potency and selectivity.
  • Promising cellular activity was observed, indicating potential therapeutic relevance.

Conclusions:

  • The novel irreversible MAP2K7 inhibitors represent a promising new class of compounds.
  • These inhibitors could serve as valuable tools for studying pediatric T-ALL.
  • Further development may lead to new therapeutic strategies for T-ALL.